Trachoma: a review.

Area of Science:

• Ophthalmology
• Infectious Diseases
• Microbiology

Background:

• Trachoma is a significant cause of preventable blindness globally.
• Caused by Chlamydia trachomatis, its transmission is linked to factors like child presence, overcrowding, and poor water access.
• Initial symptoms include follicular conjunctivitis, potentially leading to severe ocular complications like scarring, vision loss, and trichiasis.

Purpose of the Study:

• To evaluate the efficacy and pharmacokinetic profile of a single oral dose of azithromycin in treating trachoma.
• To understand the drug's persistence in conjunctival tissue for effective trachoma management.

Main Methods:

• Clinical assessment of trachoma patients.
• Administration of a single oral dose of azithromycin.
• Analysis of conjunctival biopsy specimens to determine azithromycin levels over time.
• Microbiological analysis including Minimum Inhibitory Concentration (MIC) for Chlamydia trachomatis.

Main Results:

• Azithromycin was found to be safe and effective in children with active trachoma.
• Single oral doses of azithromycin achieved sustained high drug concentrations in conjunctival tissue for up to two weeks in adult patients.
• These levels remained above the Minimum Inhibitory Concentration (MIC) required for Chlamydia trachomatis.

Conclusions:

• A single oral dose of azithromycin is a suitable and effective treatment for endemic trachoma.
• The drug's prolonged presence in ocular tissues supports its use in mass drug administration programs.
• Further research into the mechanisms of Chlamydial tissue damage and scarring is warranted.